Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal responseNaveen Pemmaraju, Jacqueline S. Garcia, Rami S. Komrokji et al.|Blood Neoplasia|2024Cited by 12
A Phase 1b, Open-Label Study of Eftozanermin Alfa in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple MyelomaPaul G. Richardson, Philippe Moreau, Akshanth R. Polepally et al.|Blood|2020Cited by 3